by Plus Therapeutics | Dec 25, 2024 | Uncategorized
Missed Plus Therapeutics at SNO Annual 2024? Catch Our Latest Presentations Online – Including ReSPECT-LM Phase 1 Interim Data If you weren’t able to attend the SNO Annual Meeting 2024 this year, don’t worry – you can now access all our key presentations online! This...
by Plus Therapeutics | Dec 23, 2024 | Uncategorized
🎄 Happy Holidays from Plus Therapeutics! 🎄 As the end of year year approaches, the Plus Therapeutics team wants to extend our warmest holiday greetings to all of our patients, partners, and supporters. We are taking some time this week to relax and recharge with our...
by Plus Therapeutics | Dec 3, 2024 | Uncategorized
Plus Therapeutics Expands Strategic Partnership with Telix IsoTherapeutics for Rhenium-186 Radioisotope Supply BREAKING NEWS: Plus Therapeutics is pleased to announce the expansion of our strategic agreement with Telix IsoTherapeutics Group, a move that strengthens...
by Plus Therapeutics | Nov 28, 2024 | Uncategorized
Thankful for the Oncology Community: Celebrating Patients, Caregivers, and Medical Advancements As we take time to reflect on the progress in the field of oncology, Plus Therapeutics extends our deepest gratitude to the patients, caregivers, and the dedicated medical...
by Plus Therapeutics | Nov 15, 2024 | Uncategorized
ICYMI: Watch the Plus Therapeutics Q3 2024 Conference Call Webcast Replay Catch up on the latest financial results and updates from Plus Therapeutics! If you missed yesterday’s conference call, don’t worry – you can still access the webcast replay to hear...
by Plus Therapeutics | Nov 9, 2024 | Uncategorized
Join Plus Therapeutics at the Upcoming 5K Event in New York! Meet Our Patient Advocacy Team Speaking about ReSPECT-GBM and Recurrent Glioblastoma Don’t miss the chance to visit the Plus Therapeutics booth at the ABTA NYC community 5K next week in New York! We’re...
Recent Comments